Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: lyratherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2024 | $12.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
| 5/7/2024 | $10.00 → $0.50 | Buy → Hold | Jefferies |
| 5/7/2024 | Buy → Underperform | BofA Securities | |
| 5/6/2024 | Outperform → Mkt Perform | William Blair | |
| 10/6/2023 | $15.00 | Buy | BTIG Research |
| 8/31/2023 | $12.00 | Buy | H.C. Wainwright |
| 5/24/2022 | $15.00 | Overweight | Cantor Fitzgerald |
Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies
Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension study indicating no product-related serious adverse events and general consistency with the primary treatment phase WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the third quarter ended September 30, 2024 and provided a corporate up
-- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN 2 clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN
WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the Company will present results from the Phase 3 ENLIGHTEN 1 study for LYR-210, the company's lead product candidate for CRS, at the 70th Annual Meeting of the American Rhinologic Society (ARS), taking place September 27-28 in Miami. The Company will also present additional results from the Phase 2 BEACON study for LYR-220 in adult patients with CRS who have had prior ethmoid sinus surgery at the Annual
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned – – In parallel, the company continues to analyze data from ENLIGHTEN 1; further analysis of the ENLIGHTEN 1 data has revealed that LYR-210 demonstrated improvement over control in symptomatic endpoints in the CRS patient cohort with nasal polyps – WATERTOWN, Mass., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusi
WATERTOWN, Mass., April 26, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) (the "Company" or "Lyra"), a clinical-stage biotech developing long-acting, anti-inflammatory sinonasal implants for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 78,400 shares of Lyra Therapeutics common stock to 16 new non-executive employees as an inducement material to their acceptance of employment with Lyra Therapeutics. The employment inducement awards were approved by Lyra's independent directors serving on its Compensation Committee and granted under Lyra's 2022 Employment Inducement Award Plan, as amende
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 119,200 shares of Lyra common stock to 18 new non-executive employees as an inducement material to their acceptance of employment with Lyra. The employment inducement awards were approved by Lyra's independent directors serving on its Compensation Committee and granted under the Company's 2022 Inducement Award Plan, as amended, and related form
WATERTOWN, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in November: Jefferies London Healthcare Conference 2023 – Fireside chat on Thursday, November 16th at 1:30 p.m. GMTPiper Sandler 35th Annual Healthcare Conference – Presentation on Wednesday, November 29th at 9:30 a.m. ET Live webcast of the presentations will be available on the Investor Relations section of the Company's website at
WATERTOWN, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA), a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that Maria Palasis, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences in September: H.C. Wainwright 25th Annual Global Investment Conference – Fireside chat on Wednesday, September 13th at 2:00 p.m. ETCantor Global Healthcare Conference 2023 – Fireside chat on Tuesday, September 26th at 4:20 p.m. ET Live webcast of the presentations will be available on the Investor Relations section of the Company's w
WATERTOWN, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the pivotal Phase 3 ENLIGHTEN I clinical trial of LYR-210 in adult patients with CRS who have not had prior ethmoid sinus surgery, is fully enrolled. LYR-210 is a bioresorbable nasal implant designed to deliver six months of continuous anti-inflammatory medication (mometasone furoate; MF) to the sinonasal passages for the treatment of CRS. Topline results from ENLIGHTEN I are expected in the first half of
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
H.C. Wainwright downgraded Lyra Therapeutics from Buy to Neutral and set a new price target of $2.00 from $12.00 previously
Jefferies downgraded Lyra Therapeutics from Buy to Hold and set a new price target of $0.50 from $10.00 previously
BofA Securities downgraded Lyra Therapeutics from Buy to Underperform
William Blair downgraded Lyra Therapeutics from Outperform to Mkt Perform
BTIG Research resumed coverage of Lyra Therapeutics with a rating of Buy and set a new price target of $15.00
H.C. Wainwright initiated coverage of Lyra Therapeutics with a rating of Buy and set a new price target of $12.00
Cantor Fitzgerald initiated coverage of Lyra Therapeutics with a rating of Overweight and set a new price target of $15.00
4 - Lyra Therapeutics, Inc. (0001327273) (Issuer)
Accomplished financial executive with extensive strategic and operational leadership in emerging growth and commercial stage healthcare companies Extensive experience in private and public equity financings with more than $1 billion raised Incendia Therapeutics, a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve cancer outcomes, today announced the appointment of Bradford Smith as Chief Financial Officer (CFO). Smith is an accomplished financial executive with more than 30 years of strategic and operational leadership in emerging growth and commercial stage healthcare companies
SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13D/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
SC 13G/A - Lyra Therapeutics, Inc. (0001327273) (Subject)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
DEFA14A - Lyra Therapeutics, Inc. (0001327273) (Filer)
10-Q - Lyra Therapeutics, Inc. (0001327273) (Filer)
8-K - Lyra Therapeutics, Inc. (0001327273) (Filer)
DEFA14A - Lyra Therapeutics, Inc. (0001327273) (Filer)
DEF 14A - Lyra Therapeutics, Inc. (0001327273) (Filer)
PRE 14A - Lyra Therapeutics, Inc. (0001327273) (Filer)
S-8 - Lyra Therapeutics, Inc. (0001327273) (Filer)
10-K - Lyra Therapeutics, Inc. (0001327273) (Filer)